Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex reversal of profound rocuronium-induced neuromuscular blockade in Chinese and European surgical subjects
2007-007162-38Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Mar 2008
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of Sugammadex (2 arms), sponsored by Organon & Co. Primary endpoints: Key efficacy objective in Chinese subjects and Key efficacy objective in Caucasian subjects. Started Mar 2008; status: completed.
02
Drugs
Sugammadex
Beyond the preview
Go deeper on 2007-007162-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007162-38.